247 related articles for article (PubMed ID: 23659854)
1. Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Gomes-da-Silva LC; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):356-64. PubMed ID: 23659854
[TBL] [Abstract][Full Text] [Related]
2. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
3. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
4. Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.
Gomes CP; Gomes-da-Silva LC; Ramalho JS; de Lima MC; Simões S; Moreira JN
Curr Gene Ther; 2013 Jun; 13(3):189-201. PubMed ID: 23531193
[TBL] [Abstract][Full Text] [Related]
5. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Bu Y; Yang Z; Li Q; Song F
Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
[TBL] [Abstract][Full Text] [Related]
6. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
8. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
Sakurai Y; Hatakeyama H; Akita H; Harashima H
Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640
[TBL] [Abstract][Full Text] [Related]
9. [Enhancive effect of PLK1 gene silencing on sensitivity of K562/A02 cells to adriamycin].
Liu L; Zhang M; Zou P; Tian L; Liu F
Ai Zheng; 2006 Apr; 25(4):404-8. PubMed ID: 16613670
[TBL] [Abstract][Full Text] [Related]
10. RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.
Kolosenko I; Edsbäcker E; Björklund AC; Hamil AS; Goroshchuk O; Grandér D; Dowdy SF; Palm-Apergi C
J Control Release; 2017 Sep; 261():199-206. PubMed ID: 28684168
[TBL] [Abstract][Full Text] [Related]
11. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.
Gomes-da-Silva LC; Santos AO; Bimbo LM; Moura V; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Int J Pharm; 2012 Sep; 434(1-2):9-19. PubMed ID: 22617794
[TBL] [Abstract][Full Text] [Related]
12. Dual sensitive and temporally controlled camptothecin prodrug liposomes codelivery of siRNA for high efficiency tumor therapy.
Li Y; Liu R; Yang J; Ma G; Zhang Z; Zhang X
Biomaterials; 2014 Dec; 35(36):9731-45. PubMed ID: 25189519
[TBL] [Abstract][Full Text] [Related]
13. Lipopolyplexes comprising imidazole/imidazolium lipophosphoramidate, histidinylated polyethyleneimine and siRNA as efficient formulation for siRNA transfection.
Gonçalves C; Berchel M; Gosselin MP; Malard V; Cheradame H; Jaffrès PA; Guégan P; Pichon C; Midoux P
Int J Pharm; 2014 Jan; 460(1-2):264-72. PubMed ID: 24225347
[TBL] [Abstract][Full Text] [Related]
14. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
[TBL] [Abstract][Full Text] [Related]
15. [Effect of PLK1 gene silence on cell cycle, proliferation and drug resistance in K562/A02 cells].
Liu L; Zhang M; Zou P; Tian L; Liu F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Apr; 14(2):241-6. PubMed ID: 16638189
[TBL] [Abstract][Full Text] [Related]
16. [Knockdown of PLK1 mRNA by special siRNA].
Chen GX; Dong QH; Zhang JW; Fu FF; Xu ZF; Liang QY; Zheng S; Ding JY
Yi Chuan; 2006 Jan; 28(1):21-5. PubMed ID: 16469711
[TBL] [Abstract][Full Text] [Related]
17. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
18. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
19. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
[TBL] [Abstract][Full Text] [Related]
20. [Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells].
Han DP; Cui JT; Lu AG; Chen XH; Feng B; Zong YP; Qu S; Cao QF; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jan; 14(1):61-4. PubMed ID: 21271384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
